{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:28:33Z","timestamp":1784618913328,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and LDL particle number (LDL-PN). The presence of atherosclerotic cardiovascular disease (ASCVD) increases the risk of future cardiovascular events. We evaluated the efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor, alirocumab, among individuals with type 2 diabetes (T2DM), high LDL-C or non-HDL-C, and established ASCVD receiving maximally tolerated statin in ODYSSEY DM-DYSLIPIDEMIA (NCT02642159) and DM-INSULIN (NCT02585778).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In DM-DYSLIPIDEMIA, individuals with T2DM and mixed dyslipidemia (non-HDL-C\u2009\u2265\u2009100\u00a0mg\/dL; n\u2009=\u2009413) were randomized to open-label alirocumab 75\u00a0mg every 2\u00a0weeks (Q2W) or usual care (UC) for 24\u00a0weeks, with UC options selected before stratified randomization. In DM-INSULIN, insulin-treated individuals with T2DM (LDL-C\u2009\u2265\u200970\u00a0mg\/dL; n\u2009=\u2009441) were randomized in a double-blind fashion to alirocumab 75\u00a0mg Q2W or placebo for 24\u00a0weeks. Study participants also had a glycated hemoglobin\u2009&lt;\u20099% (DM-DYSLIPIDEMIA) or\u2009&lt;\u200910% (DM-INSULIN). Alirocumab dose was increased to 150\u00a0mg Q2W at week 12 if week 8 LDL-C was\u2009\u2265\u200970\u00a0mg\/dL (DM-INSULIN) or non-HDL-C was\u2009\u2265\u2009100\u00a0mg\/dL (DM-DYSLIPIDEMIA). Lipid reductions and safety were assessed in patients with ASCVD from these studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This analysis included 142 DM-DYSLIPIDEMIA and 177 DM-INSULIN participants with ASCVD, including 95.1% and 86.4% with coronary heart disease, and 32.4% and 49.7% with microvascular diabetes complications, respectively. At week 24, alirocumab significantly reduced LDL-C, non-HDL-C, ApoB, and LDL-PN from baseline versus control. This translated into a greater proportion of individuals achieving non-HDL-C\u2009&lt;\u2009100\u00a0mg\/dL (64.6% alirocumab\/23.8% UC [DM-DYSLIPIDEMIA]; 65.4% alirocumab\/14.9% placebo [DM-INSULIN]) and ApoB\u2009&lt;\u200980\u00a0mg\/dL (75.1% alirocumab\/35.4% UC and 76.8% alirocumab\/24.8% placebo, respectively) versus control at week 24 (all <jats:italic>P\u2009<\/jats:italic>&lt;\u20090.0001). In pooling these studies, 66.4% (alirocumab) and 67.0% (control) of individuals reported treatment-emergent adverse events. The adverse event pattern was similar with alirocumab versus controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Among individuals with T2DM and ASCVD who had high non-HDL-C\/LDL-C levels despite maximally tolerated statin, alirocumab significantly reduced atherogenic cholesterol and LDL-PN versus control. Alirocumab was generally well tolerated.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Clinicaltrials.gov. NCT02642159. Registered 30 December 2015 and Clinicaltrials.gov. NCT02585778. Registered 23 October 2015<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0951-9","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T09:02:52Z","timestamp":1573290172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct02642159","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02585778","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kausik K.","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"M\u00fcller-Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Tinahones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Domenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Letierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Bujas-Bobanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,9]]},"reference":[{"key":"951_CR1","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S13\u201327.","journal-title":"Diabetes Care"},{"key":"951_CR2","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:3168\u2013209.","journal-title":"J Am Coll Cardiol"},{"key":"951_CR3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verges","year":"2015","unstructured":"Verges B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58:886\u201399.","journal-title":"Diabetologia"},{"key":"951_CR4","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/dom.13257","volume":"20","author":"KK Ray","year":"2018","unstructured":"Ray KK, Leiter LA, Muller-Wieland D, et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab. 2018;20:1479\u201389.","journal-title":"Diabetes Obes Metab"},{"key":"951_CR5","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103\u201323.","journal-title":"Diabetes Care"},{"key":"951_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486","author":"F Cosentino","year":"2019","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486.","journal-title":"Eur Heart J"},{"key":"951_CR7","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107.","journal-title":"N Engl J Med"},{"key":"951_CR8","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/dom.13114","volume":"19","author":"LA Leiter","year":"2017","unstructured":"Leiter LA, Cariou B, Muller-Wieland D, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017;19:1781\u201392.","journal-title":"Diabetes Obes Metab"},{"key":"951_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-017-0552-4","volume":"16","author":"D M\u00fcller-Wieland","year":"2017","unstructured":"M\u00fcller-Wieland D, Leiter LA, Cariou B, et al. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovasc Diabetol. 2017;16:70.","journal-title":"Cardiovasc Diabetol"},{"key":"951_CR10","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137:1571\u201382.","journal-title":"Circulation"},{"key":"951_CR11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350\u20137.","journal-title":"JAMA"},{"key":"951_CR12","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","volume":"118","author":"PH Jones","year":"2016","unstructured":"Jones PH, Bays HE, Chaudhari U, et al. Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials. Am J Cardiol. 2016;118:1805\u201311.","journal-title":"Am J Cardiol"},{"key":"951_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/cpt.1193","volume":"105","author":"MT Gurgoze","year":"2019","unstructured":"Gurgoze MT, Muller-Hansma AHG, Schreuder MM, Galema-Boers AMH, Boersma E, Roeters van Lennep JE. Adverse events associated with PCSK9 inhibitors: a real-world experience. Clin Pharmacol Ther. 2019;105:496\u2013504.","journal-title":"Clin Pharmacol Ther"},{"key":"951_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1055\/s-0038-1676863","volume":"119","author":"F Paciullo","year":"2019","unstructured":"Paciullo F, Momi S, Gresele P. PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention. Thromb Haemost. 2019;119:359\u201367.","journal-title":"Thromb Haemost"},{"key":"951_CR15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun H, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:618\u201328.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"951_CR16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"951_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"951_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","volume":"140","author":"PG Steg","year":"2019","unstructured":"Steg PG, Szarek M, Bhatt DL, et al. Effect of alirocumab on mortality after acute coronary syndromes. Circulation. 2019;140:103\u201312.","journal-title":"Circulation"},{"key":"951_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4158\/CS-2018-0535","volume":"25","author":"AJ Garber","year":"2019","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American Collage of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142019 executive summary. Endocr Pract. 2019;25:69\u2013100.","journal-title":"Endocr Pract"},{"key":"951_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12933-018-0689-9","volume":"17","author":"S-H Yang","year":"2018","unstructured":"Yang S-H, Xu R-X, Cui C-J, et al. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db\/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol. 2018;17:48.","journal-title":"Cardiovasc Diabetol."},{"key":"951_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/clp.10.84","volume":"6","author":"M Elam","year":"2011","unstructured":"Elam M, Lovato L, Ginsberg H. The ACCORD-lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. Clin Lipidol. 2011;6:9\u201320.","journal-title":"Clin Lipidol."},{"key":"951_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322.","journal-title":"N Engl J Med."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0951-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-019-0951-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0951-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:17:35Z","timestamp":1628612255000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0951-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,9]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0951-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,9]]},"assertion":[{"value":"25 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi\u2019s data sharing criteria, eligible studies, and process for requesting access can be found at: .","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The study protocol was approved by local institutional review boards and\/or ethics committees. This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, consistent with Good Clinical Practices, and applicable regulatory requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from each patient prior to performing any study procedures and following adequate explanation of the aims, methods, objectives, and potential hazards of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Kausik K. Ray has received significant research grants from Pfizer Inc., Amgen, Sanofi, Regeneron Pharmaceuticals, Inc., and MSD Pharma outside of the submitted work; modest honoraria from Dr. Reddys, Zuellig Pharma, Sanofi, Amgen, Boehringer Ingelheim, Novo Nordisk, and Pfizer Inc.; and modest consultant\/advisory board fees from Medco, AstraZeneca, Resverlogix, Kowa, Abbvie, Sanofi, Amgen, Boehringer Ingelheim, Esperion, Akcea, and Regeneron Pharmaceuticals, Inc. Stefano Del Prato has received research funding from AstraZeneca, Boehringer Ingelheim, Novartis Pharmaceuticals Co., and Merck Sharpe & Dohme; and is a consultant for or has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuticals, Laboratoires Servier, Merck Sharpe & Dohme, Novartis Pharmaceuticals Co., Novo Nordisk, Sanofi, Servier, and Takeda Pharmaceuticals. Dirk M\u00fcller-Wieland has received speaker\u2019s bureau and consultant\/advisory board fees from Amgen, AstraZeneca, Boehringer Ingelheim, MSD (Merck), Novartis, Novo Nordisk, and Sanofi. Bertrand Cariou has received research funding and honoraria from Amgen, Sanofi and Regeneron Pharmaceuticals, Inc.; research funding from Pfizer; and honoraria from Abbott, Amgen, Akcea, AstraZeneca, Pierre Fabre, Genfit, Eli Lilly and Company, MSD Merck & Co., Novo Nordisk, and Servier. Helen M. Colhoun has received grants, personal fees, and non-financial support from Sanofi and Regeneron Pharmaceuticals, Inc.; grants, institutional fees, and non-financial support from Eli Lilly and Company; grants from AstraZeneca and Pfizer Inc.; and grants and fees from Novo Nordisk; and owns stock in Roche Pharmaceuticals and Bayer. Francisco J. Tinahones has received speaker\u2019s bureau and consultant\/advisory board fees from AstraZeneca, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuticals, Merck Sharpe & Dohme, Novartis Pharmaceuticals Co., Novo Nordisk, Sanofi, and Regeneron Pharmaceuticals, Inc. Catherine Domenger is an employee and shareholder in Sanofi. Alexia Letierce is an employee of and shareholder in Sanofi. Jonas Mandel is an employee of IviData Stats, contracted to Sanofi. Rita Samuel is an employee of and shareholder in Regeneron Pharmaceuticals, Inc. Maja Bujas-Bobanovic is an employee and shareholder in Sanofi. Lawrence A. Leiter has received personal fees from Esperion and HLS; grants and personal fees from Amgen, AstraZeneca, Eli Lilly and Company, Merck, Regeneron Pharmaceuticals, Inc., and Sanofi; and grants from Kowa and The Medicines Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}